Nasus Pharma Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NSRX research report →
Companywww.nasuspharma.com
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
- CEO
- Dan Teleman
- IPO
- 2025
- Employees
- 2
- HQ
- Tel Aviv, IL
Price Chart
Valuation
- Market Cap
- $23.60M
- P/E
- -16.20
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -15.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,532,000 · -45.77%
- EPS
- $-0.17 · -41.67%
- Op Income
- $-1,078,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $9.99
- 52W Low
- $1.98
- 50D MA
- $2.87
- 200D MA
- $5.97
- Beta
- 3.89
- Avg Volume
- 213.76K
Get TickerSpark's AI analysis on NSRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 22, 26 | Teleman Dan Benjamin | buy | 2,900 |
| Mar 31, 26 | Teleman Dan Benjamin | buy | 15,000 |
| Nov 20, 26 | Rubin Eyal | other | 40,549 |
| Mar 11, 26 | Silberman David | other | 10,000 |
| Mar 18, 26 | Teleman Dan Benjamin | other | 0 |
| Jan 7, 26 | Teleman Dan Benjamin | other | 318,856 |
| Mar 11, 26 | Shacham Sharon | other | 10,000 |
| Mar 18, 26 | Gilboa Udi | other | 0 |
| Mar 18, 26 | Gilboa Udi | other | 0 |
| Feb 13, 26 | Gilboa Udi | other | 17,970 |
Our NSRX Coverage
We haven't published any research on NSRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NSRX Report →